The use of recommended vaccinations among patients with chronic diseases in relation to attitudes toward vaccination and anxiety levels Authors: Anna Lewandowska, Tomasz Lewandowski, Grzegorz Rudzki, Michał Próchnicki, Anna Bartosiewicz, Aleksandra Stryjkowska-Góra, Tomasz Góra, Barbara Zych, Barbara Laskowska, Agnieszka Bielec, Beata Bida Published: 2025 ABSTRACT BackgroundAccording to the guidelines of the European Centre for Disease Control and Prevention, a specialized vaccination protocol is recommended for individuals with chronic conditions such as asplenia, diabetes, cardiovascular diseases, HIV infection, liver diseases, pulmonary diseases, kidney diseases, and immunodeficiency. The recommended vaccinations for chronically ill patients include the seasonal influenza vaccine, periodic booster doses of tetanus, diphtheria, and pertussis vaccines, the herpes zoster vaccine, and the pneumococcal vaccine. Since December 2020, the COVID-19 vaccine has also been recommended for this group. The aim of the study was to assess the use of recommended vaccinations in patients with chronic diseases, to analyze factors influencing patients’ attitudes towards vaccinations, as well as the severity of fear of getting sick and the correlation of fear with attitudes towards vaccinations.MethodsA cross-sectional study with comparison groups was conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. A convenience sampling method was applied, and the study was carried out among oncology patients, patients with chronic obstructive pulmonary disease (COPD), and healthy individuals in the control group. The study utilized a survey questionnaire, the Positive Health Behavior Scale, and the SL-C Trait Anxiety Scale.ResultsThe study group included patients with cancer, patients with obstructive pulmonary disease, and healthy controls. The most frequently received vaccination was against COVID-19, both in the group of oncology patients (74%), in the group of patients with obstructive pulmonary disease (65%) and in the control group (85%). The percentage of influenza vaccinations was higher in patients with COPD (OR: 1.6, p < 0.05) compared to patients with cancer or the control group. Furthermore, a significant increase in recommended vaccinations was observed in age groups ≥ 65 years (OR: 1.9, p < 0.01) compared to younger age groups in both groups I and II. Fear of severe illness (47%) was the main reason for vaccination. Participants learned about vaccines primarily from the internet (35%). The occurrence of side effects after vaccination did not significantly influence the decision to revaccinate (chi-square = 0.24, p = 0.622).ConclusionsPatients are most willing to be vaccinated against COVID-19, while the percentage of vaccinations with other recommended vaccines in clinical risk groups is below the desired level. Due to the high percentage of people vaccinated against COVID-19 and the mild course of the disease in most cases, it can be concluded that vaccination provided high protection against severe disease and hospitalization among vulnerable groups of the population.Clinical trialNot applicable. Introduction Protective vaccinations are widely acknowledged by public health authorities and the medical community as a fundamental tool for achieving success in the field of public health. The World Health Organization estimates that protective vaccinations prevent between 2 and 3 million deaths annually [1]. The effectiveness and significance of immunization in combating infectious diseases have been repeatedly demonstrated throughout history. Thanks to vaccination programs, it has been possible to completely eliminate diseases such as smallpox, which had persisted for approximately 3,000 years and was associated with a mortality rate of around 30%. In Poland and many other countries, the incidence of diseases such as measles and pertussis has also been significantly reduced. Protective vaccination remains the most effective method of preventing infectious diseases currently known to humanity. The challenges in treating viral infections, their rapid mutation rates, and the difficulty in developing effective therapies make vaccines the primary means of protection against numerous diseases, many of which are characterized by severe clinical courses [2]. Protective vaccinations are of particular importance for patients belonging to high-risk groups for severe disease progression and death resulting from infectious diseases. This increased risk is primarily due to impairments in humoral or cellular immunity, quantitative and functional deficiencies in the immune system, immunosenescence, and chronic conditions treated with immunosuppressive drugs or high doses of cytostatics [3–6]. The risk of severe infectious disease is several times higher among patients with chronic illnesses, hematologic malignancies, lung cancer, metastatic tumors, and solid tumors within the first year of cancer diagnosis. In the general population, the risk is estimated at approximately 2–3%, whereas among oncology patients it ranges from 5% to 61%. Cancer patients are exposed to a high risk of serious complications, with the probability of death estimated at 25.6% [7, 8]. According to the guidelines of the European Centre for Disease Control and Prevention, a specialized vaccination protocol is recommended for individuals with chronic diseases such as asplenia, diabetes, cardiovascular diseases, HIV infection, liver diseases, pulmonary diseases, kidney diseases, and immunodeficiency. The recommended protective vaccinations for chronically ill patients include the seasonal influenza vaccine, periodic booster doses of tetanus, diphtheria, and pertussis vaccines, the herpes zoster vaccine, and the pneumococcal vaccine. Since December 2020, the COVID-19 vaccine has also been recommended for this group [9, 10]. Patients undergoing chemotherapy for solid tumors or hematologic malignancies should be vaccinated against invasive pneumococcal disease and seasonal influenza. A booster dose of diphtheria, tetanus, and polio vaccines is also required six months after the completion of treatment [11]. The European Society for Medical Oncology (ESMO) has issued statements supporting COVID-19 vaccination among oncology patients [4, 12]. Despite detailed national and international recommendations, the vaccination rate among chronically ill and immunocompromised patients remains far from satisfactory. This study hypothesized that oncology patients and those with other chronic immunosuppressive conditions are rarely vaccinated. It aimed to investigate patients’ attitudes toward recommended protective vaccinations, analyze factors influencing these attitudes, identify barriers to vaccination, assess the intensity of anxiety related to illness, and determine whether anxiety correlates with attitudes toward vaccination. Identifying obstacles to immunization may enable the development of strategies to improve vaccination coverage. Materials and methods Study design A descriptive, cross-sectional study with comparison groups was conducted in 2024 following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Study participants The study was conducted among oncology patients and patients with chronic obstructive pulmonary disease (COPD) treated at the Clinical Hospital in Rzeszów, located in the Podkarpackie Voivodeship. The control group consisted of healthy people visiting their relatives during hospitalization and declaring no chronic diseases. The convenience purposive sampling method was used. The study was conducted based on the following inclusion criteria: age 18 years or older, informed consent to participate in the study, a confirmed diagnosis of cancer or COPD (for the patient groups), health status allowing participation, and self-reported absence of any chronic disease in the control group. Exclusion criteria included: lack of consent to participate, age below 18 years, cognitive impairment preventing logical communication with the patient, and health conditions posing a risk to the participant’s safety. After obtaining informed consent, a total of 400 questionnaires were distributed across all groups. Of these 270 were returned, resulting in response rate of 67%. The final analysis included all 270 correctly completed questionnaires. Instruments The study used a survey questionnaire, the Positive Health Behavior Scale, and the SL-C Trait Anxiety Scale. The survey questionnaire includes detailed and comprehensive instructions on how to complete the survey. It contains open-ended, single-choice, and multiple-choice questions, allowing for the collection of demographic, epidemiological, and qualitative information. The questionnaire is divided into general and specific sections. The general section covers demographic data such as gender, age, education, and employment status. The specific section contains questions related to vaccination and assesses attitudes towards protective vaccinations. The Positive Health Behavior Scale is a standardized questionnaire consisting of 29 health-related statements. Respondents are asked to rate on a scale from 0 to 3, the extent to which they engage in preventive health behaviors in their daily lives. The Polish version of the Positive Health Behavior Scale (PHBS) for use in adults was used. Cronbach’s α for the whole scale amounted to 0.825 [12]. The SL-C Scale is a tool used to measure the intensity of anxiety as a personality trait, understood as the tendency to perceive future events as threatening or dangerous, manifested through specific symptoms at the emotional, cognitive, somatic, and behavioral levels. The SL-C Scale consists of 15 items, with responses given on a four-point scale from never to often. Each response is scored as follows: never-0, rarely-1, sometimes-2, often-3, except for items 9 and 11, where never-3, rarely-2, sometimes-1, often-0. The SL-C Scale scores are the sum of all points obtained. The scores range from 0 (the lowest intensity of anxiety traits) to 45 (the highest intensity of anxiety traits). The Polish version of the trait anxiety scale, the State-Trait Anxiety Inventory (STAI), was used. The Cronbach’s alpha reliability coefficient for the SL-C scale was 0.862 [12]. Data collection The questionnaire was reviewed for clarity and feasibility prior to the commencement of data collection. The prepared research tool was verified to ensure it accurately measures the phenomenon we aim to understand. A pilot survey was conducted with 30 patients, not included in the final sample, to evaluate the clarity and comprehensiveness of the instrument. The pilot study allowed for verification of the survey questionnaire, checking whether all questions were clear and understandable to respondents, whether they were understood in accordance with the researcher’s intentions and whether they provided the desired information. Subsequently, the main study began, with each respondent being informed by the researcher about the purpose and significance of the study and that participation was entirely voluntary. Envelopes containing information about the study, the informed consent form, and the questionnaire were distributed to all respondents, who were asked to return them to the researcher after completion. No objections were reported by the respondents while answering the questions in the questionnaire. Definitions of proper vaccination According to the recommendations of the Chief Sanitary Inspector in Poland, numerous vaccinations are advised for adults, particularly those belonging to high-risk groups, to protect against serious diseases and their complications. The main vaccinations recommended in the Protective Vaccination Program include: influenza (administered annually, especially recommended for older adults, individuals with weakened immunity, organ transplant recipients, and cancer patients), COVID-19, pneumococci (particularly recommended for individuals with immune disorders, diabetes, chronic heart diseases, liver cirrhosis, pulmonary or renal diseases), herpes zoster (especially recommended for individuals over 50 years of age and those with weakened immunity), hepatitis B (for unvaccinated individuals), diphtheria, tetanus, and pertussis (booster dose every 10 years). Sample The oncology patient group consisted of 53% women and 47% men, with an average age of 59.51 years (SD = 7.76). Among patients with chronic obstructive pulmonary disease (COPD), 52% were women and 48% were men, with a mean age of 53.55 ± 6.53 years. The control group comprised healthy individuals, with 77% women and 23% men. The average age of the participants in this group was 48.41 ± 6.76 years. Ethical considerations The study was approved by the Team for Scientific Research Ethics at the Bioethics Committee at Collegium Masoviense University of Health Sciences in Zyrardow and the Institute of Healthcare of the State University of Technology and Economics in Jaroslaw, no. 197/2022. All study participants gave their informed consent to participate in the study, and none of the participants expressed objection or withdrew from participation. Data analysis The study’s results were analyzed using Statistica softwere (version 22.0,TIBCO Software Inc.). Independent variables included in the multivariate logistic regression models were those associated with bivariate analysis, using chi-square test for the categorical variables, and Student’s t-test for continuous, with p-value less or equal to 0.25. A stepwise procedure was used to build the final models and the significance levels for exclusion and inclusion of variables were p-values of 0.4 and 0.2, respectively. The results of the logistic regression analyses were reported as odds ratios (ORs) and 95% confidence intervals (CIs). All inferential tests were two-tailed and determinants were considered significantly associated with the outcome for p-values equal to or less than 0.05. Results Demographic data of the study groups The first study group consisted of oncology patients (Cases I) with a mean age of 59.51 years (SD = 7.76). Within this group, women accounted for 53% and men for 47% of participants. The majority of respondents were urban residents (69%) and professionally inactive (63%). The second group included patients with chronic obstructive pulmonary disease (Cases II), with a mean age of 53.5 years (SD = 6.53). This group comprised 52% women and 48% men. The majority of respondents were rural residents (56%) and economically inactive people (59%). The control group consisted of healthy individuals without any diagnosed chronic disease, including 77% women and 23% men. The average age of participants in this group was 48.41 years (SD = 6.76). The majority of respondents were city residents (70%) and professionally active people (91%). Other descriptive statistics identifying the study group are presented in Table 1. Table 1Descriptive statistics among all respondentsDemographic InformationCases ICases IIControls P Characteristics % (N)Sexwomen53% (143)52% (140)77% (208)0.01men47% (127)48% (130)23% (62)The age of the study groupSD59.51 (7.76)53.55 (6.53)48.41 (6.76)0.1295%CI< 18; 80>< 21; 69>< 25; 60>Place of residencecity69% (186)44% (119)70% (189)0.21village31% (84)56% (151)30% (81)Financial situationvery good10% (27)15% (41)13% (35)0.01good42% (113)38% (102)58% (156)average34% (92)30% (81)18% (49)bad12% (33)10% (27)10% (27)very bad2% (5)7% (19)1% (3)Age groups18–301% (3)14% (38)12% (33)0.0131–405% (13)11% (30)20% (54)41–5010% (27)14% (38)25% (68)51–6028% (76)36% (97)38% (102)61–7038% (102)20% (54)5% (13)71–8018% (49)5% (13)0% (0)Educationprimary8% (22)4% (11)10% (27)0.01vocational35% (95)23% (62)47% (127)Secondary32% (86)42% (113)24% (65)higher25% (67)31% (84)19% (51)Marital statusmarried68% (183)57% (153)74% (200)0.62widowed11% (30)8% (22)2% (5)unmarried21% (57)35% (95)24% (65)Professional activityprofessionally active37% (100)41% (111)91% (246)0.01unemployed5% (13)9% (24)2% (5)pension4% (11)7% (19)7% (19)retirement54% (146)43% (116)0%(0) Table 1Descriptive statistics among all respondentsDemographic InformationCases ICases IIControls P Characteristics % (N)Sexwomen53% (143)52% (140)77% (208)0.01men47% (127)48% (130)23% (62)The age of the study groupSD59.51 (7.76)53.55 (6.53)48.41 (6.76)0.1295%CI< 18; 80>< 21; 69>< 25; 60>Place of residencecity69% (186)44% (119)70% (189)0.21village31% (84)56% (151)30% (81)Financial situationvery good10% (27)15% (41)13% (35)0.01good42% (113)38% (102)58% (156)average34% (92)30% (81)18% (49)bad12% (33)10% (27)10% (27)very bad2% (5)7% (19)1% (3)Age groups18–301% (3)14% (38)12% (33)0.0131–405% (13)11% (30)20% (54)41–5010% (27)14% (38)25% (68)51–6028% (76)36% (97)38% (102)61–7038% (102)20% (54)5% (13)71–8018% (49)5% (13)0% (0)Educationprimary8% (22)4% (11)10% (27)0.01vocational35% (95)23% (62)47% (127)Secondary32% (86)42% (113)24% (65)higher25% (67)31% (84)19% (51)Marital statusmarried68% (183)57% (153)74% (200)0.62widowed11% (30)8% (22)2% (5)unmarried21% (57)35% (95)24% (65)Professional activityprofessionally active37% (100)41% (111)91% (246)0.01unemployed5% (13)9% (24)2% (5)pension4% (11)7% (19)7% (19)retirement54% (146)43% (116)0%(0) Descriptive statistics among all respondents History of chronic disease In the group of oncology patients, breast cancer was more frequently diagnosed among women (25%), while colorectal cancer was more common among men (28%). These differences were statistically significant (p < 0.0001). The most commonly reported duration of illness was between 6 and 12 months (41%). A cancer diagnosis within the past 6 months was reported by 23% of participants, while 17% had been ill for 1 to 2 years. In the remaining cases, the disease had been present for more than 2 years. The duration of cancer did not differ significantly between women and men (p = 0.6208). The most common treatment modality among oncology patients was chemotherapy (39%) (Table 2). Among patients with COPD, the most frequently reported duration of illness was up to one year (33%), followed by 1 to 2 years (11%), 3 to 5 years (23%), 5 to 10 years (18%), and over 10 years (15%). A total of 40% of patients described their disease course as mild, 28% as moderate with a low risk of exacerbation, and 11% as severe. Additionally, 21% of respondents were unable to determine the severity of their condition. Table 2History of oncological patientsVariableSex P WomenMenCharacteristics % (N) Type of cancer diagnosed breast25% (68)0% (0)0.01cervical4% (11)0% (0)0.05lung49% (132)45% (121)0.13colon6% (16)28% (76)0.01stomach4% (11)13% (35)0.14pancreatic2% (5)0% (0)0.25prostate0% (0)11% (30)0.12ovarian8% (22)0% (0)0.66skin2% (5)3% (8)0.17 Type of therapy used chemotherapy55% (148)21% (57)0.38radiotherapy6% (16)6% (16)0.11immunotherapy13% (35)17% (46)0.13hormone therapy6% (16)4% (11)0.41surgical treatment21% (57)51% (138)0.38 Table 2History of oncological patientsVariableSex P WomenMenCharacteristics % (N) Type of cancer diagnosed breast25% (68)0% (0)0.01cervical4% (11)0% (0)0.05lung49% (132)45% (121)0.13colon6% (16)28% (76)0.01stomach4% (11)13% (35)0.14pancreatic2% (5)0% (0)0.25prostate0% (0)11% (30)0.12ovarian8% (22)0% (0)0.66skin2% (5)3% (8)0.17 Type of therapy used chemotherapy55% (148)21% (57)0.38radiotherapy6% (16)6% (16)0.11immunotherapy13% (35)17% (46)0.13hormone therapy6% (16)4% (11)0.41surgical treatment21% (57)51% (138)0.38 History of oncological patients History of infectious diseases COVID-19 infection was confirmed in 27% of oncology patients and 61% of patients with chronic obstructive pulmonary disease (COPD). The results did not significantly differ based on gender, age, or place of residence (p = 0.4778). Hospitalization due to severe COVID-19 infection occurred in 4% of oncology patients and 7% of COPD patients (p = 0.6976). In the control group, more than half of the participants (73%) had contracted COVID-19. The analysis showed that the incidence of COVID-19 among respondents did not significantly correlate with age, gender, or place of residence. Only 6% of participants assessed the course of infection as severe; however, none required hospitalization. Other infectious diseases reported by participants included influenza, with 67% of oncology patients, 71% of COPD patients, and 25% of individuals in the control group having experienced the illness. Cases of pertussis were rare (7% of oncology patients, 10% of COPD patients, and 1% of the control group), as were cases of herpes zoster (1% of oncology patients). Recommended vaccinations Among oncology patients, the most commonly received vaccine was the COVID-19 vaccine (74%). Other vaccinations included the influenza vaccine (25%) and the pneumococcal vaccine (9%). A greater sense of safety following vaccination was reported by 47% of patients, while 26% confirmed experiencing adverse effects post-vaccination. In the group of COPD patients, the most frequently received vaccine was also the COVID-19 vaccine (65%), followed by the influenza vaccine (39%), the pneumococcal vaccine (10%), and the diphtheria and tetanus vaccine (4%). A greater sense of safety after vaccination was reported by 61% of patients, and 20% confirmed experiencing adverse effects. Among respondents in the control group, 85% received the COVID-19 vaccine, while 15% were vaccinated against influenza (Table 3). The rate of influenza vaccination was higher among COPD patients (OR: 1.6, p < 0.05) compared to oncology patients and the control group. Furthermore, a significant increase in recommended vaccinations was observed in age groups ≥ 65 years (OR: 1.9, p < 0.01) compared to younger age groups in both Case I and Case II groups. Fear of severe illness (47%) was the primary reason for receiving vaccinations (Table 3). Respondents most commonly obtained information about vaccines from the Internet (35%) (Fig. 1). The occurrence of side effects following vaccination did not significantly influence the decision to receive future vaccinations (χ² = 0.24, p = 0.622). Table 3Vaccination characteristics for all respondentsVariableCases ICases IIControlsRR(95% CI) P Characteristics % (N) Symptoms after vaccination pain, swelling at injection site47% (127)43% (116)50% (135)1.16 (1.07–1.36)0.03fever9% (24)8% (22)26% (70)1.16 (0.72–1.87)0.01fatigue18% (49)5% (13)49% (132)2.18 (1.32–4.06)0.03headache26% (70)2% (5)58% (157)2.07 (1.14–3.77)0.22muscle pain31% (84)7% (19)25% (67)0.98 (0.49–1.3)0.37weakness45% (121)2% (5)11% (30)1.51 (0.75–3.93)0.20difficulty breathing4% (11)2% (5)8% (22)0.70 (0.49–1.3)0.37 Reasons for vaccination fear of severe illness47% (127)57% (153)45% (121)1.06 (0.99–1.03)0,14doctor’s order9% (24)23% (62)1% (3)1.53 (0.84–3.32)0,14fear of complications26% (70)11% (30)12% (32)0,98 (0.75–1.28)0.41contact with many people18% (49)1% (3)6% (16)0.92 (0.65–1.29)0.72 Table 3Vaccination characteristics for all respondentsVariableCases ICases IIControlsRR(95% CI) P Characteristics % (N) Symptoms after vaccination pain, swelling at injection site47% (127)43% (116)50% (135)1.16 (1.07–1.36)0.03fever9% (24)8% (22)26% (70)1.16 (0.72–1.87)0.01fatigue18% (49)5% (13)49% (132)2.18 (1.32–4.06)0.03headache26% (70)2% (5)58% (157)2.07 (1.14–3.77)0.22muscle pain31% (84)7% (19)25% (67)0.98 (0.49–1.3)0.37weakness45% (121)2% (5)11% (30)1.51 (0.75–3.93)0.20difficulty breathing4% (11)2% (5)8% (22)0.70 (0.49–1.3)0.37 Reasons for vaccination fear of severe illness47% (127)57% (153)45% (121)1.06 (0.99–1.03)0,14doctor’s order9% (24)23% (62)1% (3)1.53 (0.84–3.32)0,14fear of complications26% (70)11% (30)12% (32)0,98 (0.75–1.28)0.41contact with many people18% (49)1% (3)6% (16)0.92 (0.65–1.29)0.72 Vaccination characteristics for all respondents The figure presents the distribution of declared sources of information on COVID-19 vaccinations among oncology patients (Cases I, n = 125), COPD patients (Cases II, n = 110), and healthy controls (Controls, n = 35). Respondents could select multiple sources: Internet, doctor, media (TV/radio/press), and family. Percentages reflect the proportion of participants in each group who indicated a given source. The most frequently reported source among COPD patients was the Internet (62%), while healthy controls most often cited doctors (41%). Use of family as a source was generally low across all groups (Fig. 1). Fig. 1Sources of knowledge about COVID-19 vaccinations Sources of knowledge about COVID-19 vaccinations Attitudes toward vaccination A positive overall attitude toward vaccination was expressed by 45% of oncology patients. The results were not significantly associated with the gender of the respondents (p = 0.2124). According to 57% of oncology patients, vaccination does not provide complete protection against illness. Furthermore, 60% of oncology patients believed that vaccination had no impact on their cancer treatment. The stage of disease in the studied group did not significantly correlate with the decision to receive vaccination (p = 0.199). Among patients with chronic obstructive pulmonary disease (COPD), 36% demonstrated a positive attitude toward vaccination, while as many as 47% were unconvinced about its effectiveness, and 64% stated they did not intend to get vaccinated in the future. In the control group, 37% of respondents believed that vaccinations are effective and exhibited a positive attitude. A statistical analysis was conducted to examine the relationship between receiving recommended vaccinations and attitudes toward vaccination. A statistically significant association was found (p = 0.029) between having received vaccinations in the past and the decision to get vaccinated. No statistically significant influence of education level on the decision to get vaccinated was observed (χ² = 3.05, p = 0.384 at a significance level of p < 0.05). Similarly, no significant association was found between education level and willingness to receive vaccination in the future (χ² = 5.37, p = 0.147). It was also shown that the stage of disease in the studied group did not significantly correlate with the decision to receive vaccination in the past (χ² = 4.65, p = 0.199), nor did it significantly influence the willingness to get vaccinated in the future (χ² = 5.37, p = 0.147). Although it was observed that higher scores on the Positive Health Behavior Scale were associated with a greater likelihood of deciding to get vaccinated, this relationship was not statistically significant (χ² = 4.78, p = 0.310). Similarly, higher scores on the scale were linked to a greater willingness to get vaccinated in the future, but again, no statistically significant association was found (χ² = 5.31, p = 0.257). However, patients who demonstrated better health behaviors were more likely to get vaccinated (OR: 1.5, p < 0.01) (Table 4). Table 4Reasons for refusing to take the vaccine among all respondentsReasons for refusalCases ICases IIControlsRR(95% CI) P Characteristics % (N)Concerns about vaccine safety17% (46)21% (57)47% (127)1.53 (0,84 − 2,77)0.09Doubts about the vaccine’s effectiveness10% (27)18% (49)24% (65)2.18 (0.87–6.35)0.14Fear of complications after vaccination16% (43)25% (67)41% (111)1.16 (0.72–1.87)0.01Vaccine too expensive18% (49)22% (59)19% (51)0.98 (0.75–1.28)0.19Lack of time2% (5)7% (19)19% (51)0.92 (0.65–1.29)0.71Lack of reliable information35% (94)32% (86)13% (35)0,98 (0.75–1.28)0.37 Table 4Reasons for refusing to take the vaccine among all respondentsReasons for refusalCases ICases IIControlsRR(95% CI) P Characteristics % (N)Concerns about vaccine safety17% (46)21% (57)47% (127)1.53 (0,84 − 2,77)0.09Doubts about the vaccine’s effectiveness10% (27)18% (49)24% (65)2.18 (0.87–6.35)0.14Fear of complications after vaccination16% (43)25% (67)41% (111)1.16 (0.72–1.87)0.01Vaccine too expensive18% (49)22% (59)19% (51)0.98 (0.75–1.28)0.19Lack of time2% (5)7% (19)19% (51)0.92 (0.65–1.29)0.71Lack of reliable information35% (94)32% (86)13% (35)0,98 (0.75–1.28)0.37 Reasons for refusing to take the vaccine among all respondents Experienced anxiety A total of 47% of oncology patients reported no anxiety prior to vaccination. Moderate levels of anxiety were experienced by 38% of respondents, while 29% reported high levels of anxiety. Among patients with chronic obstructive pulmonary disease (COPD), 56% did not experience anxiety before vaccination; however, 43% reported high levels of anxiety (Table 5). Analysis based on the SL-C Trait Anxiety Scale revealed that anxiety intensity varied significantly with age (p = 0.038). Individuals under the age of 60 experienced, on average, higher levels of anxiety. A correlation analysis using Spearman’s rho coefficient confirmed a relationship between attitudes toward protective vaccinations and anxiety. Negative attitudes toward vaccination were positively associated with anxiety levels. However, the relationship between anxiety and attitudes is weak and should be interpreted with caution (rho = 0.27; p < 0.001). In the control group, 68% of respondents reported no anxiety prior to vaccination. Moderate levels of anxiety were experienced by 29%, while 23% reported high levels of anxiety. The SL-C scale analysis showed that anxiety intensity differed significantly by gender (p = 0.038), with women experiencing, on average, higher levels of anxiety than men. The relationship between anxiety intensity and age was close to the threshold of statistical significance (p = 0.061). Slightly higher levels of anxiety were observed among younger participants (under 40 years of age) compared to older participants (aged 40 and above). Table 5Feeling of anxiety about vaccination among all respondentsLevel of anxiety intensityCases ICases IIControlsRR(95% CI) P Characteristics % (N)Low37% (100)36% (97)48% (130)1.64 (0.81–2.47)0.22Medium38% (103)21% (57)29% (78)1.07 (1.15–1.47)0.01High25% (67)43% (116)23% (62)0.92 (0.45–1.29)0.31 Table 5Feeling of anxiety about vaccination among all respondentsLevel of anxiety intensityCases ICases IIControlsRR(95% CI) P Characteristics % (N)Low37% (100)36% (97)48% (130)1.64 (0.81–2.47)0.22Medium38% (103)21% (57)29% (78)1.07 (1.15–1.47)0.01High25% (67)43% (116)23% (62)0.92 (0.45–1.29)0.31 Feeling of anxiety about vaccination among all respondents Discussion The number of individuals suffering from immunosuppressive conditions and chronic diseases is steadily increasing. According to the World Health Organization (WHO) and the Centers for Disease Control and Prevention, people over the age of 60 or those with chronic conditions such as hypertension, diabetes, cardiovascular diseases, chronic respiratory diseases, compromised immune systems, and cancer are at higher risk of severe disease progression and mortality due to infectious diseases [13, 14]. Due to their condition, immunosuppressive therapy, or advanced age, these patients are more susceptible to complications from infections, including vaccine-preventable ones. In those with chronic illnesses, infections can worsen overall health. For COPD patients, pathogens like influenza virus, Bordetella pertussis, and Streptococcus pneumoniae may trigger respiratory infections and exacerbate symptoms [15]. Data from various sources, including meta-analyses, indicate that cancer patients face a significantly higher risk of severe illness and death from infectious diseases [16–18]. Vaccination reduces both morbidity and mortality, which is especially important in high-risk groups [8]. Accordingly the National Comprehensive Cancer Network COVID-19 Vaccination Advisory Committee recommends prioritizing vaccination for patients with active cancer and those undergoing treatment [19, 20]. Cancer and its treatment often lead to reduced overall health and weakened immunity. Despite this, COVID-19 vaccines have proven effective in cancer patients, who are encouraged to receive boosters and are kept informed about vaccine safety [4]. However, vaccine skepticism remains, influenced by patients’ knowledge and attitudes toward immunization [21]. Numerous studies show that patients’ willingness to get vaccinated depends on their beliefs, physician recommendations, and socioeconomic status. French surveys often cite male gender, older age, and prior influenza vaccination as predictors of acceptance [22]. The report Chronic Diseases and Attitudes Toward Vaccination found the highest vaccine acceptance among patients with immunological and oncological diseases, while those with other chronic conditions such as asthma, most often identified as moderate supporters (55.6%) [23]. In the present study, fewer than 10% of patients were vaccinated against diphtheria, tetanus, or pneumococcal disease. COVID-19 vaccination was reported by 74% of oncology patients and 65% of those with COPD. Influenza vaccination rates were lower: 29% and 25%, respectively consistent with other findings. For influenza, uptake remains well below the WHO/EU target of 75% for high-risk groups. Similarly, in the WHO European Region, detection rates below 40% have been reported among individuals with chronic diseases in 14 other European countries. Regarding pneumococcal vaccination, other studies have also demonstrated low coverage rates, ranging from 7% in Italy to 50% among immunocompromised patients in the United States and 60% in high-risk groups in Spain [15]. In Boey et al.‘s study, 30% were vaccinated against diphtheria/tetanus, 10% against pertussis, 44% against influenza, and 32% against pneumococcal disease, with COPD patients showing the highest diphtheria/tetanus and influenza coverage [15]. Similarly, Miki et al. reported a 76% SARS-CoV-2 vaccination rate [24]. Our study also found that individuals aged 65 + were more likely to be vaccinated against influenza and pneumococcal disease [15]. In Ireland, vaccination rates were 28% among at-risk adults under 65, and 16% among those over 65. Overall adult rates were 60% for influenza and 36% for pneumococcal disease [15]. Our study found that most patients had a positive attitude toward vaccination. In Germany, 95.5% of oncology patients trusted the safety and efficacy of the COVID-19 vaccine [12]. In contrast, Khari et al. reported that in Tunisia, three-quarters of patients believed the vaccines were unsafe and ineffective, and doubted the authorities’ capacity to vaccinate the population [21]. Globally, the highest acceptance rates were seen in East and Southeast Asia (>90%), while the lowest occurred in the Middle East, Russia, Africa, and parts of Europe [21]. As in many studies, the main reasons for vaccine refusal or hesitancy were concerns about efficacy and lack of trust. Distrust in vaccines is widespread and can be reinforced by negative messaging, especially via media or family, which is linked to reduced vaccine confidence and uptake [24–26]. Giese et al. found that concerns about influenza vaccine efficacy and side effects lowered interest, while a perceived lack of necessity was the top reason for skipping it among at-risk adults under 65. For the pneumococcal vaccine, the main issue was lack of awareness—fewer than 30% of patients reported being informed about it [27]. According to the Public Opinion Research Center report, 69% of respondents feared vaccine side effects, and 25% doubted its effectiveness [28]. In Bouloukaki et al.’s study, 65% of of asthma and COPD patients had concerns about vaccine efficacy and safety [29]. In Australia, hesitancy was most common among younger people and significantly higher in women [30]. Kufel-Grabowska found that 56% of patients feared cancer progression more than COVID-19, affecting vaccine uptake [31]. Similarly, Bartoszkiewicz et al. reported that 40% of cancer patients were concerned about vaccine safety [32], and in a large Mexican study, 36% declined vaccination due to side effect fears [33]. In contrast, 70% of oncology patients in China expressed confidence in vaccine safety [5]. In our study, 47% of oncology patients reported no fear of vaccination. Negative attitudes were linked to anxiety, though Heyne et al. found no association between vaccination status and general anxiety symptoms. Most participants showed low anxiety levels. Notably, vaccinated individuals had fewer obsessive thoughts about infection [4]. Given the low vaccination coverage, greater efforts are needed to improve vaccination uptake among high-risk patients. Based on the findings, well-ostructured, multi-component vaccination campaigns should be implemented, focusing on better documentation and clear recommendations from healthcare providers. Such strategies have significantly increased vaccination rates [34]. Additionally, vaccinology education delivered by physicians and nurses can further boost patient awareness and vaccine acceptance. Strengths and limitations of the study A key strength of this study is the assessment of the uptake of recommended vaccinations in a large and diverse group of high-risk patients. The inclusion of a control group allowed for comparison with individuals not burdened by chronic illness. Data on vaccination coverage in high-risk groups are scarce and often not systematically monitored. Existing studies frequently focus on a single vaccine within a specific risk group. This study also incorporated the measurement of anxiety and health behaviors using reliable, validated tools to evaluate their influence on attitudes toward vaccination. Furthermore, we were able to collect data on a highly relevant and timely issue among a critically important patient population within our healthcare system. The results of this study should be interpreted with caution because of some methodological limitations. The cross-sectional design does not allow for establishing causal relationships between the outcomes of interest and predictors. A convenience sample of patients and a control group was used, which introduces bias. Furthermore, the recruitment of patients with chronic diseases from hospitals in a single geographic region in Poland may affect the generalizability of the results. Our study relied on patient-reported data, and some results should be interpreted with caution, especially questions regarding vaccination status, which were not confirmed in medical records and are susceptible to self-report bias. Conclusions The results of this study are important because they help highlight gaps in knowledge and uptake of recommended vaccinations among patients with chronic diseases. In summary, efforts should be made to closely monitor vaccination status in high-risk groups, systematically maintain vaccination records accessible to patients, and ensure effective physician-patient communication regarding vaccinations. It is important to promote appropriate health behaviors, implement preventive strategies, and provide ongoing and well-structured health education on vaccinations tailored to the needs of risk groups.